ITB-MED AB
559017-9429ActiveDeveloping novel antibody therapy to eliminate post-transplant immunosuppression needs.
Overview
- 10–19
- Employees
- 50–100M SEK
- Revenue
- 2015
- Founded
Description
ITB-MED is a specialized biotechnology company focused on transforming organ transplantation outcomes. The organization is developing TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody. This novel therapy aims to achieve transplantation tolerance, potentially freeing pa...
Tags
Keywords
Company Information
- Industry
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Legal Form
- Aktiebolag
- VAT Number
- SE559017942901
Decision Makers
No decision makers found yet
Similar Companies
20 similar companies in FunnelfeedriCoat Medical AB
1–4 employeesDeveloping drugs to improve organ transplantation outcomes globally.
iCoat Medical Operations AB
Developing drugs to improve organ transplantation outcomes globally.
GLYCOREX TRANSPLANTATION AB (PUBL)
10–19 employeesDevelops technology to remove blood antibodies for transplants and disease.
Circio AB
Developing circular RNA expression systems for enhanced gene therapies.
Sangair AB
3 employeesDeveloping revolutionary blood treatment technology to combat severe sepsis infections.
Browse More
ITB-MED AB Questions
Want to see Funnelfeedr in action?
Book a free demo and discover how Funnelfeedr helps you find and convert your ideal customers.
Book a demo